december 21, 2016
FOR IMMEDIATE RELEASE: Lexington, MA, December 20, 2016 /PRNewswire    — scPharmaceuticals, Inc., a privately held biopharmaceutical company    developing transformative pharmaceutical products for subcutaneous delivery announced    today that it entered into a long-term commercial supply agreement and associated    tools manufacturing agreement with Raumedic AG (Helmbrechts, Germany) for the    single-use component of its...
Oncolytic virus therapy utilizes modified viruses like the adenovirus (otherwise known as the common cold virus) that selectively replicate within tumor cells and not within normal tissue. Such viruses stimulate an inflammatory response in the tumor microenvironment, resulting in the accumulation of tumor infiltrating lymphocytes. The NG-348 virus uses PsiOxus’ proprietary Tumor-Specific Immunogene Therapy (T-SIGn) platform to “arm” the...
Mr Westberg replaces Offer Nonhoff, who is to leave after four-and-a-half-years with the company. Richard Davies, CEO of BONESUPPORT, said: “I am very pleased to welcome Björn to the BONESUPPORT team. He brings with him a wealth of finance and management experience that I am confident will be crucial to the future growth and development...


Syv forskningsinstitutioner får 20 mio. kr. til corona-forskning
1. april 2020
Sådan håndterer vi ændring af forskningsprojekter under corona-pandemien
31. marts 2020
Første Corona-bevilling fra Lundbeckfonden til forsøg med et kendt lægemiddel
26. marts 2020


Lundbeckfonden Ventures

Lundbeckfonden Emerge